An Exploratory, Open-Label Study to Assess the Effects of AZD2171 [cediranib] on Tumors and Biomarkers in Patients With Previously Untreated or Recurrent Non-Small Cell Lung Cancer (NSCLC) or Patients With Metastatic or Recurrent Head and Neck Cancer (HNC).

Trial Profile

An Exploratory, Open-Label Study to Assess the Effects of AZD2171 [cediranib] on Tumors and Biomarkers in Patients With Previously Untreated or Recurrent Non-Small Cell Lung Cancer (NSCLC) or Patients With Metastatic or Recurrent Head and Neck Cancer (HNC).

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Oct 2013

At a glance

  • Drugs Cediranib; Gefitinib
  • Indications Head and neck cancer; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Apr 2009 Planned end date changed from Apr 2009 to Jul 2009 as reported by ClinicalTrials.gov.
    • 01 Apr 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top